January 2026 in “Yonsei Medical Journal” Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
December 2025 in “International Neurourology Journal” Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
December 2025 in “Instituto Politécnico do Porto” Patients with mood disorders using 5α-reductase inhibitors may have a higher risk of suicidal thoughts.
December 2025 in “Molecular Pharmaceutics” Combining tadalafil and finasteride improves their solubility and effectiveness.
December 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” A new combination of tadalafil and finasteride improves drug performance and stability.
November 2025 in “Urology” CPDC offers significant cost savings on men's health medications compared to Medicare and GoodRx.
November 2025 in “BMC Urology” Larger prostate size, longer surgery, and smoking increase risks, while finasteride and experienced surgeons reduce them during prostate surgery.
November 2025 in “The Journal of Sexual Medicine” Using Mark Cuban Cost Plus Drug Company can save money on men's health medications compared to Medicare.
October 2025 in “Journal of the Endocrine Society” Finasteride lowers cholesterol but doesn't reduce heart-related events.
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
July 2025 in “Saudi Journal of Medicine and Public Health” 5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
June 2025 in “Experimental and Сlinical Urology” Predstanormix Duo is a safe and effective new drug for treating urinary symptoms from BPH.
June 2025 in “Reactions Weekly” Finasteride may increase the risk of depression and suicidal thoughts.
May 2025 in “Journal of Drug Delivery and Therapeutics” Combining modern and Unani medicine may improve BPH treatment with fewer side effects.
April 2025 in “The Journal of Urology” Long-term finasteride use may lower prostate cancer risk but increase the need for erectile dysfunction medication.
March 2025 in “Scientific Reports” Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.
March 2025 in “International Journal For Multidisciplinary Research” Computational techniques can improve drug development for treating certain conditions.
February 2025 in “Ciencia Latina Revista Científica Multidisciplinar” Finasteride can help with hair loss and prostate issues but may negatively affect mood and the nervous system.
December 2024 in “Frontiers in Endocrinology” Continued research and awareness are needed to improve treatments for androgen-dependent diseases.
November 2024 in “Nanomaterials” The nanocrystalline suspension effectively delivers dutasteride over time with minimal inflammation.
September 2024 in “Frontiers in Neuroendocrinology” 5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.
Higher doses of 5α-reductase inhibitors reduce mortality risk, while lower doses increase suicide risk.
June 2024 in “Ecotoxicology and Environmental Safety” Finasteride harms Daphnia magna's reproduction, growth, and metabolism.
June 2024 in “Drug and therapeutics bulletin” Finasteride can cause depression, suicidal thoughts, and lasting psychiatric and sexual issues.
April 2024 in “The Journal of urology/The journal of urology” SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.
December 2023 in “Magna Scientia Advanced Research and Reviews” The document suggests using trazodone and clomiphene to treat sexual dysfunction caused by post-finasteride syndrome.
December 2023 in “Natural product research” Lignans from Urtica triangularis may help treat benign prostatic hyperplasia (BPH).
December 2023 in “Alzheimer's & Dementia” Long-term use of a drug for hair loss and prostate issues can cause metabolic problems and depression-like behavior in young male rats.